← Back to Calendar

BT8009

Bicycle Therapeutics · $BCYC
Standard Review Phase 2 Fast Track
Catalyst Date
September 1, 2026
Time Remaining
141 days
Review Type
Standard (10 mo)

Live Company Data NMS

Updated just now · Data: FMP
Current Price
$4.94 -24.35%
$-1.59 today
Day: $4.87 – $5.01
Market Cap
N/A
Shares out: 50.27M
52-Week Range
$4.24
$9.55
Current price is at 13% of 52-week range
Avg Volume
444K
Beta
1.65
vs. S&P 500
Sector
Healthcare
Biotechnology
⚠️ Financial data is for informational purposes only. Not investment advice. Prices may be delayed.
Track $BCYC catalysts → get weekly FDA alerts Subscribe Free on Substack →

Indication

Metastatic urothelial carcinoma (Nectin-4 targeted)

Key Notes

DUET-2 Phase 2 trial data expected Q3 2026. BT8009 is a Nectin-4–targeted Bicycle Toxin Conjugate (BTC) — differentiated from ADCs with potentially improved tumor penetration in bladder cancer.
⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.

Discussion

Share your analysis, research, or questions about this catalyst. No account required.

Rate limit: 5/hr per email
Loading comments...
← Back to Full Calendar